Spinal Cord Series and Cases, 2024 · DOI: https://doi.org/10.1038/s41394-024-00632-7 · Published: March 28, 2024
NeuroAiD (MLC601 & MLC901) has neuroprotective capabilities including limiting exaggerated calcium influx, decreasing excitotoxicity, reducing oxidative stress, and preventing glutamate-induced cell death. It also facilitates synaptogenesis, neurogenesis, and neuroplasticity. This case report presents a 34-year-old male with complete tetraplegia who regained considerable neurological recovery following MLC901 supplementation for 6 months. The patient exhibited motor recovery beyond the initial zone of partial preservation up to 24 months post injury, suggesting potential benefits of NeuroAiD in facilitating recovery during post-acute and chronic phases of severe SCI.
NeuroAiD (MLC901) may be considered as a potential therapeutic intervention to facilitate neurological recovery in patients with complete SCI, particularly in the post-acute and chronic phases.
Large-scale randomized controlled trials are necessary to establish the definitive role of NeuroAiD in SCI and to determine its specific impact on neurological recovery at different phases of SCI.
Further investigation is needed to determine if the neurological improvement brought about by NeuroAiD can be translated into functional gains for patients with SCI.